TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules, and uses thereof
AssigneeNewsoara Biopharmaceutical Technology (Suzhou) Co., Ltd.
InventorsWenyi Wang, Qingqing Yin, Yuannian Li
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules that simultaneously target TL1A and IL-23p19. The disclosure also relates to nucleic acid molecules encoding said antigen-binding molecules, expression vectors, host cells, compositions thereof, and their use for treating diseases.
Claims23
A bispecific antigen-binding molecule comprising a first antigen-binding functional region and a second antigen-binding functional region, wherein the first antigen-binding functional region comprises at least one antigen-binding unit targeting TL1A comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein:
- the VH comprises an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 26, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 27, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 28, and the VL comprises an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 17, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 18, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 29;
- and the second antigen-binding functional region comprises at least one immunoglobulin single variable domain specifically binding to IL-23p19 comprising:
- a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 52, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 53, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 54.
Dependencies are inferred from the claim text.